Skip to Content

Posts tagged with "Cancer"

  • Cancer

    It’ll Cost You

    Over at Slate, NBC’s Robert Bazell takes on the drug pricing issue, focusing on the newer oncology therapies. There’s no denying that some of them are really costly, and that this is a situation that probably can’t continue under the current system (which, to exaggerate only slightly, works like this: every cancer patient gets to… Read More
  • Business and Markets

    Vox Populi

    I wasn’t planning on returning to this topic today, but tonight’s e-mail seems to deserve a speedy reply. Says a loyal reader, one “Busterbuckeye”: You gave me a very impolite back hand slap in the above referenced blog. . .(on May 12) I posted in response to your April 28 blog in which you quoted… Read More
  • Business and Markets

    As Goes ASCO. . .

    The American Society of Clinical Oncology meeting is taking place as you read this. ASCO is a pretty high-pressure venue, because key clinical results for cancer therapies are often unveiled there. The audience has a much higher percentage of journalists and financial analysts than you’ll see at most meetings. It’s a sandstorm of hype,… Read More
  • Cancer

    All the Myriad Ways

    Closely related to the patenting of biochemical pathways is the patenting of genes. I’m not completely thrilled with that, either, but it still makes a bit more sense to me. With these patents, you own the gene and uses for it, but you don’t get to claim everything else downstream of it (like the protein… Read More
  • Business and Markets

    Deferred Gratification Is Better Than None At All

    Bad days for Genta and Allos, as the FDA first made their advisory committee minutes public on Friday, then turned down their drug applications yesterday. Both are nominally cancer therapeutics, and both were seen as tests of a supposedly more open attitude at the FDA, but they’re very different situations. Genta is, at first glance… Read More
  • Business and Markets


    The real news on the cancer front is in the post below, but I have a few other things to take care of tonight, too. Yesterday’s post on Imclone’s stock price was not well-received over on the IMCL message boards on Yahoo, where I’ve picked up several of the usual responses. They include the standard-issue… Read More
  • Business and Markets

    Foaming Up Over the Edge

    It’s been a wild time recently in the oncology field – well, not so much scientifically as financially. OSI took a huge leap the other day on good clinical news about Tarceva, the drug they’re developing with Genentech. I’ll gloss over the fact that I owned OSI stock at one point, and sold it in… Read More
  • Biological News

    A New Cancer Target – Maybe

    In my industry, you hear a lot of talk about drug targets and their relative chances of success. Targets fall into several broad classes, and when you take a close look, there are clearly some that are easier to hit than others. The G-protein coupled receptors (GPCRs) are one of those (antihistamines and beta-blockers are… Read More
  • Alzheimer's Disease

    Back on the Air

    After a (reasonably) refreshing holiday break, Lagniappe is back. Thanks to everyone who kept doggedly hitting this site during the last few days – I admire your persistance. I notice from my site’s counter that I get a small but steady flow of Google hits for various miracle cures. I said some nasty things about… Read More
  • Cancer

    Pneumonia, of All Things

    There seems to be something odd going on with Iressa, AstraZeneca’s great oncology hope. In Japan (the only place where it’s on the market,) there’s been an unusually high incidence of interstitial pneumonia among its patients. The FDA has scheduled a December meeting, almost certainly to talk about this situation and how it affec… Read More